Baidu
map

常喝含咖啡因咖啡或可降低患基底细胞癌风险

2012-07-09 任海军 新华网

  美国哈佛大学医学院研究人员日前完成的研究显示,常喝含咖啡因的咖啡有助于降低患常见皮肤癌——基底细胞癌的风险。相关研究报告本周发表在美国《癌症研究》杂志上。   基底细胞癌是最常见的皮肤恶性肿瘤,常发作于面部。在国外,半数以上皮肤癌患者患的是基底细胞癌。美国国家癌症研究所的数据显示,美国每年约有百万人接受基底细胞癌治疗。研究人员分析了参加“健康职业跟踪研究”和“护士健康研究”的11.2万人为期

  美国哈佛大学医学院研究人员日前完成的研究显示,常喝含咖啡因的咖啡有助于降低患常见皮肤癌——基底细胞癌的风险。相关研究报告本周发表在美国《癌症研究》杂志上。

  基底细胞癌是最常见的皮肤恶性肿瘤,常发作于面部。在国外,半数以上皮肤癌患者患的是基底细胞癌。美国国家癌症研究所的数据显示,美国每年约有百万人接受基底细胞癌治疗。研究人员分析了参加“健康职业跟踪研究”和“护士健康研究”的11.2万人为期20多年的数据后发现,每天饮用3杯以上含咖啡因咖啡的女性患基底细胞癌的风险比每月饮用不到一杯者低21%;对类似的男性而言,风险降低10%。

  他们还发现,经常摄入含咖啡因的茶或巧克力也可以发挥同样功效,但不能降低患鳞状细胞癌、黑素瘤及其他皮肤癌的风险;饮用不含咖啡因的咖啡与患基底细胞癌的风险之间没有关联。

  研究人员表示,此前的小鼠试验表明,咖啡因能够抑制肿瘤增长,这项研究表明咖啡因在人体中或许也能发挥类似作用。

    



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994066, encodeId=b8411994066f8, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Aug 22 14:24:00 CST 2012, time=2012-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061329, encodeId=37a920613298b, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Dec 28 19:24:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978331, encodeId=418b19e833148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue May 28 03:24:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263909, encodeId=728a1263909fa, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Jul 11 07:24:00 CST 2012, time=2012-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994066, encodeId=b8411994066f8, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Aug 22 14:24:00 CST 2012, time=2012-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061329, encodeId=37a920613298b, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Dec 28 19:24:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978331, encodeId=418b19e833148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue May 28 03:24:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263909, encodeId=728a1263909fa, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Jul 11 07:24:00 CST 2012, time=2012-07-11, status=1, ipAttribution=)]
    2012-12-28 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994066, encodeId=b8411994066f8, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Aug 22 14:24:00 CST 2012, time=2012-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061329, encodeId=37a920613298b, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Dec 28 19:24:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978331, encodeId=418b19e833148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue May 28 03:24:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263909, encodeId=728a1263909fa, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Jul 11 07:24:00 CST 2012, time=2012-07-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994066, encodeId=b8411994066f8, content=<a href='/topic/show?id=a6c4420601d' target=_blank style='color:#2F92EE;'>#基底细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42060, encryptionId=a6c4420601d, topicName=基底细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Aug 22 14:24:00 CST 2012, time=2012-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061329, encodeId=37a920613298b, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Dec 28 19:24:00 CST 2012, time=2012-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978331, encodeId=418b19e833148, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue May 28 03:24:00 CST 2013, time=2013-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263909, encodeId=728a1263909fa, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Wed Jul 11 07:24:00 CST 2012, time=2012-07-11, status=1, ipAttribution=)]

相关资讯

FDA:皮肤基底细胞癌新药Erivedge获批

 2012年1月30日,美国食品与药物管理局(FDA)批准Erivedge(vismodegib)用于治疗成人最常见的皮肤癌——基底细胞癌。该药预期用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。   Erivedge经由优先审查程序获准,是FDA批准的首个治疗转移性基底细胞癌的药物。它通过抑制Hedgehog通路起效,这种通路在大多数基底细胞癌中活跃,但仅在少许正常组织中(

NEJM:Vismodegib被证明对基底细胞癌有效

根据6月6日《新英格兰医学杂志》发表的两项小型早期研究结果,vismodegib可有效治疗基底细胞痣综合征和进展期基底细胞癌(BCC)。 基底细胞恶性肿瘤在美国是最常见的非黑色素瘤皮肤癌之一,在210万例患者中占80%以上。这是一种严重破坏容貌的癌症,但较少危及生命。几乎所有的BCC都由hedgehog信号传导通路的改变所致。美国食品药品管理局(FDA)今年1月份批准了Vismodegib用于治疗

头颈部皮肤癌切缘阳性患者或可选择临床观察

 据美国耳鼻喉医师协会联合会议上报告的一项回顾性研究结果,头颈部皮肤癌切缘阳性患者除选择再切除术之外,观察或“观察等待”也是一种可接受的选择。 为比较头颈部皮肤癌切缘阳性患者观察等待与再切除的预后情况,西弗吉尼亚州摩根顿克拉克斯堡美国退伍军人医院的Justin Douglas博士及其同事对492例患者进行回顾性研究。患者均在5年前接受头颈部皮肤癌切除术,包括387例基底细胞癌(B

Arch Gen Psychiatry:基底细胞癌风险与早期生活压力有关

早期生活陷入亲子关系困境的人在过去一年有严重生活困扰的话可能会罹患一种最常见的皮肤癌——基底细胞癌(BCC)。这项研究发表在Archives of General Psychiatry杂志上。 文章背景资料指出,压力事件和由此产生的负面情绪可以引发人体的免疫系统功能障碍,带来临床症状的重大变化,影响基底细胞癌以及病情的发展。童年暴晒于太阳下,白皙的皮肤类型和男性性别是基底细胞癌的第一危险因素,但

Baidu
map
Baidu
map
Baidu
map